TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06077955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-gastric bypass with stapled anastomosis
Description: the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-gastric bypass with hand-sewn anastomosis
Description: the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture.
Study: NCT05180799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BA3071
Description: Conditionally active biologic (CAB) antibody that binds to CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BA3071
Description: Conditionally active biologic (CAB) antibody that binds to CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BA3071
Description: Conditionally active biologic (CAB) antibody that binds to CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BA3071
Description: Conditionally active biologic (CAB) antibody that binds to CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: pemetrexed with either cisplatin or carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: pemetrexed with either cisplatin or carboplatin
Study: NCT04730869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Plus Metabolic Therapy Program
Description: See description under Arms.
Study: NCT06265792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05096234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ 18F]F-AraG PET
Description: Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
Study: NCT06636318

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample Collection
Description: To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses.

Intervention type: DEVICE
Intervention: Actigraph (GT9X-BT) Monitor
Description: Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
Study: NCT05483231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family integrated care intervention group
Description: If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine nursing care group
Description: Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
Study: NCT05947461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg diclofenac
Description: All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg indomethacin
Description: All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
Study: NCT04867512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Tincture
Description: Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Detox
Description: GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olivirex
Description: Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
Study: NCT05528653

Intervention type: DRUG
Group type: OTHER
Intervention: Descovy
Description: HIV infection pre-exposure prophylaxis
Study: NCT05352516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX14
Description: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14.
Study: NCT06571708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab 1600mg IV
Study: NCT04952402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Community-provided Moderna mRNA-1273 COVID-19 Vaccine
Description: Participants received a two-dose series.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Description: Participants received a two-dose series.
Study: NCT04875767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)
Description: General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)
Description: General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
Study: NCT04895241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT05956093

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FAPI PET CT
Description: the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
Study: NCT06075511

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minutes walk distance
Description: Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded

Intervention type: BEHAVIORAL
Intervention: Activity Monitor
Description: Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.

Intervention type: BEHAVIORAL
Intervention: Continuous Glucose Monitor
Description: Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.

Intervention type: BEHAVIORAL
Intervention: Blood Pressure Monitoring
Description: Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure Monitoring
Description: 24-hour ambulatory blood pressure monitoring
Study: NCT05695898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb22841
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb22841
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb22841
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb23104
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb23104
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb23104
Description: Given intravenously (IV)
Study: NCT06379178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral colostrum application 2 hours
Description: Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral colostrum application 4 hours
Description: Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
Study: NCT06071130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong
Description: Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
Study: NCT06552546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
Study: NCT05723237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Education
Description: The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
Study: NCT06141109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab 200mg+MB07133 600mg
Description: 1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1.
Study: NCT05725967

Intervention type: PROCEDURE
Intervention: Primary Obesity Endoscopic Procedures
Description: Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).

Intervention type: PROCEDURE
Intervention: Endoscopic Revision of Bariatric Surgical Procedures
Description: Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.

Intervention type: PROCEDURE
Intervention: Bariatric Surgery Procedures
Description: Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)

Intervention type: DEVICE
Intervention: Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction
Description: Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.

Intervention type: DEVICE
Intervention: Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction
Description: Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.

Intervention type: DEVICE
Intervention: Intragastric Balloon
Description: An endoscopic bariatric procedure involving the placement of an intragastric balloon.

Intervention type: DEVICE
Intervention: Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal
Description: Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.

Intervention type: DEVICE
Intervention: Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal
Description: Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
Study: NCT06264869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
Description: Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interdental guided creeping technique (IGCT) and collagen membrane (CM)
Description: Interdental guided creeping technique (IGCT) and collagen membrane (CM)
Study: NCT05986305

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go Act
Description: Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer
Description: During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
Study: NCT04847375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exogenous surfactant
Description: Nebulized Surfactant would be administered by face mask which has a nebulizer
Study: NCT06522893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
Study: NCT05599282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement
Description: Four capsules of Amino Acid Supplement will be taken once a day for 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules of Placebo will be taken once a day for 90 days.
Study: NCT06238934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate matrix
Description: Bone marrow aspirate \* Hyaluronic acid

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow aspirate
Description: Bone marrow aspirate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronic acid
Study: NCT05636046

Intervention type: PROCEDURE
Intervention: transseptal catheterization
Description: puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.

Intervention type: PROCEDURE
Intervention: transseptal catheterization
Description: puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.